Argenx stock reports $1.7 billion sales before the open
Published on 10/23/2026 at 08:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly sales and pipeline updates
- argenx reported third-quarter 2026 product net sales of $1.7 billion on October 22, 2026.
- The company expects Phase 3 empasiprubart data in multifocal motor neuropathy in December 2026.
- Argenx stock trades pre-market at EUR 781.40 at 7:59 a.m. CEST at Lang & Schwarz on October 23, 2026.
argenx SE reported third-quarter 2026 product net sales of $1.7 billion on October 22, 2026, while outlining additional development milestones. At 7:59 a.m. CEST on October 23, 2026, argenx stock was at EUR 781.40 in pre-market trading at Lang & Schwarz.
Quarterly results and pipeline milestones
In its release, argenx said product net sales rose 54 percent year over year and 13 percent from the second quarter. The company reported third-quarter operating income of $1.8 billion and profit of $506 million, with diluted profit per share of $7.80. It also said its supplemental biologics license application for VYVGART Hytrulo in immune-mediated necrotizing myopathy remained on track for submission by year-end 2026.
Ahead of the Xetra open
argenx said topline results from the Phase 3 EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in December 2026. The company also expects the pediatric VYVGART filing to receive a U.S. regulatory decision in February 2027. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Argenx stock.
Immunology-focused business
argenx develops medicines for patients with underserved diseases by advancing immunology research into treatments and commercializing products such as VYVGART and VYVGART Hytrulo. The company’s next scheduled financial event is its full-year 2026 results and fourth-quarter business update on February 25, 2027. Market context: Market report Euro Stoxx 50.
